Finch Therapeutics to Present at the H.C. Wainwright Global Investment Conference
Finch Therapeutics Group, a clinical-stage microbiome therapeutics company (Nasdaq: FNCH), announced that CEO Mark Smith, PhD, will present an overview at the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Finch Therapeutics Group, a clinical-stage microbiome therapeutics company (Nasdaq: FNCH), announced that CEO Mark Smith, PhD, will present an overview at the H.C. Wainwright Global Investment Conference from May 23-26, 2022. The presentation will be available on-demand starting May 24, 2022, at 7:00 am ET. Finch focuses on developing novel orally administered biological drugs, with its lead candidate, CP101, in late-stage clinical trials for preventing recurrent C. difficile infections. The company also explores treatments for children with autism and partners with Takeda for inflammatory bowel disease therapies.
Details
News Market Reaction – FNCH
The recorded move for FNCH in the trading session of this news was +10.75%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOMERVILLE, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, today announced that Mark Smith, PhD, Chief Executive Officer, will present a company overview at the H.C. Wainwright Global Investment Conference being held May 23-26, 2022. The presentation will be available on-demand beginning on Tuesday, May 24, 2022 at 7:00 am ET.
A webcast of the presentation will be available under the ‘Investors & News’ section of the Finch website and will be archived for approximately 30 days.
About Finch Therapeutics
Finch Therapeutics is a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs. With the capabilities to develop both complete and targeted microbiome therapeutics, Finch is advancing a rich pipeline of candidates designed to address a wide range of unmet medical needs. Finch’s lead candidate, CP101, is in late-stage clinical development for the prevention of recurrent C. difficile infection and has received Breakthrough Therapy and Fast Track designations from the U.S. Food and Drug Administration. Finch is also developing FIN-211 for children with autism spectrum disorder and significant gastrointestinal symptoms. Finch has a partnership with Takeda focused on the development of targeted microbiome therapeutics for inflammatory bowel disease. Finch routinely posts information that may be important to its investors on its website at https://www.finchtherapeutics.com/. Finch encourages investors to consult the “Investors & News” section of its website regularly.
Human-First Discovery® is a registered trademark of Finch Therapeutics Group, Inc.
Investor Contact:
Stephen Jasper
Gilmartin Group
(858) 525-2047
stephen@gilmartinir.com
Media Contact:
Jenna Urban
Berry & Company Public Relations
(212) 253-8881
jurban@berrypr.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.